Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid

Leukemia

Volumn 13, Issue 8, 1999, Pages 1258-1265

  Yu, K H ^a   Weng, L J ^a   Fu, S ^a   Piantadosi, S ^a   Gore, S D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cell cycle; Differentiation; Histone deacetylase; Phenylbutyrate; Retinoic acid; Synergy

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CD11B ANTIGEN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; DRUG POTENCY; DRUG RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0032868044     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401468     Document Type: Article

References (53)

1. Gore SD, Samid D, Weng L-J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997; 3: 1755-1762.
2. Gore SD, Miller CB, Weng L-J, Burks K, Griffin CA, Chen T-L, Smith V, Burke PJ, Grever M, Rowinsky EK. Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. Anticancer Res 1997; 17: A28.
3. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379-387.
4. Bowling MK, Nelson JB, Tong KP, Simons JW, Eisenberger MA, Sinibaldi V, Donehower RC, Carducci MA. Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Am Soc Clin Oncol 1996; 15: A43.
5. WAF1/CIP1 protein expression. Proc Am Soc Clin Oncol 1996; 37: A1384.
6. Pelidis MA, Carducci MA, Simons JW. Integration of sodium phenylbutyrate into neuroblastoma therapy. Proc Am Soc Clin Oncol 1996; 15: A1596.
7. Samid D, Shack S, Myers CE. Selective growth arrest and phenyotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993; 91: 2288-2295.
8. Lea MA, Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995; 15: 879-883.
9. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994; 54: 891-895.
10. Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonzales FJ, Samid D. Activation of a peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharm 1996; 52: 659-667.
11. Craig RW, Frankfurt OS, Sakagami H, Takeda K, Bloch A. Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells. Cancer Res 1984; 44: 2421-2429.
12. Craig RW, Buchan HL. Differentiation-inducing and cytotoxic effects of tumor necrosis factor and interferon-gamma in myeloblastic ML-1 cells. J Cell Physiol 1989; 141: 46-52.
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
14. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
15. Gore SD, Miller CB, Weng L-J, Burks K, Griffin CA, Chen T-L, Burke PJ, Grever MR, Rowinsky EK. Improved hematopoiesis in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following administration of the putative differentiating agent sodium phenylbutyrate (SPB). Blood 1996; 88 (Suppl. 1): 582a.
16. Breitman TR, He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 60: 6268-6273.
17. Clark RE, Jacobs A, Lush CJ, Smith SA. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1987; 1: 763-765.
18. Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 1995; 19: 277-280.
19. Ohno R. Differentiation therapy of myelodysplastic syndromes with retinoic acid. Leuk Lymphoma 1994; 14: 401-409.
20. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndrome: results of a pilot study. Blood 1993; 82: 2967-2974.
21. Ohno R, Naoe T, Hirano M, Kobayashi M, Hirai H, Tubaki K, Oh H. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993; 81: 1152-1154.
22. Hofmann WK, Burnett AK, Kell J, Chomienne C, Ganser A, Fenaux P, Castaigne S, Burnett R, Hoelzer D. Oral 9-cis-retinoic acid (9-cis-RA) in the treatment of myelodysplastic syndromes (MDS): a pilot study. Anticancer Res 1997; 17: 3936.
23. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood 1989; 74: 1517-1524.
24. Dolbeare F, Kuo W-L, Beisker W, Vanderlaan M, Gray JW. Using monoclonal antibodies in bromodeoxyuridine-DNA analysis. Meth Cell Biol 1990; 33: 227-234.
25. Erikson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
26. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, van Pals ST, Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
27. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. Induction of gamma-globin by histone deacetylase inhibitors. Blood 1997; 90: 2075-2083.
28. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995; 9: 600-611.
29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 1984; 22: 27-55.
30. Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, Howard BH, Ozato K. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci USA 1997; 94: 11295-11300.
31. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
32. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-17179.
33. Brownell JE, Allis CD. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 1996; 6: 176-184.
34. Wolffe AP, Pruss D. Targeting chromatin disruption: transcription regulators that acetylate histones. Cell 1996; 84: 817-819.
35. Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997; 94: 5798-5803.
36. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997; 89: 373-380.
37. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997; 89: 341-347.
38. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241: 142-150.
39. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007.
40. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
41. Warrell RP Jr, He L-Z, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-1625.
42. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
43. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998; 16: 2549-2556.
44. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
45. Clark RE, Lush CJ, Jacobs A, Smith SA. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1987; 1: 763-765.
46. Koeffler HP, Heitjan D, Mertelsmann R, Kolitz JE, Schulman P, Itri L, Gunter P, Besa E. Randomized study of 13-cis-retinoic acid v placebo in the myelodysplastic disorders. Blood 1988; 71: 703-708.
47. Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR, Hoelzer D. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with ali-trans retinoic acid and haemopoietic growth factors. Br J Haematol 1995; 89: 449-456.
48. Ganser A, Seipelt G, Verbeek W, Ottmann OG, Maurer A, Kolbe K, Hess U, Elsner S, Reutzel R, Wormann B, Hiddemann W, Hoelzer D. Effect of combination therapy with all-trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994; 8: 369-375.
49. Hellstrom E, Robert KH, Samuelsson J, Lindemalm C, Grimfors G, Kimby E, Oberg G, Winqvist I, Billstrom R, Carneskog J, Dahléen M, Stockner M, Wislöff F, Öst A. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol 1990; 45: 255-261.
50. Hellstrom E, Robert KH, Soppi E, Ost A, Putkonen PO, Gahrton G. Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes. Leukemia Res 1989; 13: 1113-1121.
51. Preisler HD, Raza A, Larson R, Gregory S, Siegrist C, Goldberg J, Dong LM. Suppression of regrowth resistance and long remission durations in AML. Blood 1996; 88 (Suppl. 1): 218a.
52. Warrell RP, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med 1991; 324: 1385-1393.
53. DiGiuseppe JA, Weng L-J, Yu KH, Fu S, Kastan MB, Samid D, Gore SD. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 1999 (in press).